JZZ Technologies, Inc. Joins with GenBio, Inc., Nutrific, and NutraEdge Biosciences Corp. to Create New Bioscience Products Company Focused on Breakthrough Therapeutic Products and Research
Working with respected bioscience companies GenBio, Inc., Nutrific, and NutraEdge Biosciences Corp., JZZ Technologies, Inc. intends to launch a new bioscience products venture developing and marketing novel therapeutics utilizing natural compounds for age-related healthcare issues.
Palm Beach, Florida--(Newsfile Corp. - November 16, 2021) - JZZ Technologies, Inc. (OTC Pink: JZZI) has signed a Letter Of Intent (LOI) to join with biotech company GenBio, Inc., and bioscience company Nutrific of Aliso Viejo, California, to create a new business venture in the Life Extension and Longevity sector. The new entity, which will operate under the NutraEdge Biosciences Corp. brand, contemplates utilizing product development, research, and existing human resources of GenBio, Inc., and Nutrific in its pursuit of therapeutics for various medical ailments and age-related health issues.
Under the terms, JZZ Technologies, Inc. will acquire 100% ownership of NutraEdge Biosciences Corp.
GenBio Inc. and Nutrific are focused on rapidly developing a new range of natural extracts to enhance health. GenBio CSO, Professor Lindsay Brown, a former Professor of Biomedical Sciences, University of Southern Queensland, Australia, leads the research of the company's formulations and products.
Professor Brown is a Fellow of the International Academy of Cardiovascular Science with 35 years of scientific research that encompasses an emphasis on drugs acting on the heart and associated Rific blood vessels and endocrine organs.
GenBio CEO Giles Tilley has been involved with and directed international research into rare extracts since 2010 and initially worked alongside the pioneering investigational scientific teams who made a major medical breakthrough with a natural extract. He then amassed further worldwide research with other scientific teams who were also investigating specific properties for the same new, disruptive molecular platforms for pain relief, anti-inflammation, and age-related health issues.
In 2014, Mr. Tilley was the first person to bring the rare extract to the United States for further phytochemical research. The subsequent medical findings, which have global implications for medication, make it imperative to take the research through an Investigational New Drug (IND) Program and into licensing. GenBio, Inc. intends to be the first company in the world to isolate and fractionate core molecules based on its remarkable findings.
Nutrific continues to refine an entirely new range of never seen before nutraceuticals for various medical ailments, immune boost, and human life extension in this area.
The venture between JZZ Technologies, Inc. and NutraEdge Bioscience Corp. will focus on three prolific target markets with significant projected growth over the next decade:
Anti-inflammatory Market: Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics, estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$130.9 Billion by 2026.
Pain Management Market: The global pain management drugs market was valued at $71,431.85 million in 2019 and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.
Anti-aging Market: From $194.4 billion in 2020, the global market for anti-aging treatments is set to cross $422.8 billion by 2030, at an 8.6% CAGR between 2021 and 2030.
The new NutraEdge Biosciences brand venture will focus initially on five therapeutic products in these well-defined medical categories:
- Heart Health
- Immune Support
All of the healthcare products to be introduced on an expedited basis will include the following criteria:
- Novel rare extracts
- Bioactive Australian Honey
- Manufacturing protocols to ensure the integrity of active enzymes and molecules and are not compromised
- Backed by peer-reviewed scientific journals
The key to NutraEdge Biosciences Corp.s' continuing strategy is its strong focus on the commercialization of the five initial therapeutic products supported by well-designed market development strategies with global application. This creates the opportunity to address massive untapped areas of the target markets and provide commercialization of its products, related research, and "spin-off" health products.
JZZ Technologies will arrange for capital to initiate the research and ongoing development of products under the NutraEdge Biosciences Corp. umbrella. JZZ Technologies also intends to use its entire cadre of digital marketing platforms to bolster the rollout and continuous commercial application of products.
Giles Tilley, CEO of GenBio, Inc. states, "This new licensing venture with JZZ Technologies, as envisioned, will give us an immediate leg up on the commercialization of our breakthrough nutraceutical formulas. These are important, potentially life-changing products aimed at vast natural healthcare markets. We have a strong background in the early formulation and development of rare, largely unknown bioactive extracts. JZZ Technologies brings a whole new dimension to our business through their funding capabilities with access to capital markets, as well as proprietary sales and marketing channels. We are well aligned to complement the JZZ Technologies' business model and foresee tremendous and rapid progress as our new venture launches, along with a lucrative partnership."
Charles Cardona, CEO of JZZ Technologies, Inc., stated, "We are very excited to be working with the world-class team that GenBio, Inc., Nutrific, and NutraEdge Biosciences Corp. bring to the table. Our focus is acting as a platform to deliver products that can potentially improve life quality and contribute to human longevity. We are confident that the NutraEdge Biosciences venture will play an industry-leading role in this important space."
Management expects that the transaction will close at the conclusion of a standard 30-day due diligence period.
About GenBio Inc.
Based in Aliso Viejo, California, GenBio, Inc. (www.genbioinc.com) is an early-stage biotechnology company researching novel therapeutics from a variety of extracts. Based on recent US research, the company has created an Investigational New Drug (IND) research program from novel natural compounds that are highly effective as anti-inflammatory agents. CSO, Professor Lindsay Brown, is a renowned international researcher leading GenBio's product development and research. The company also has access to other global scientific teams that are investigating specific properties for the same new, disruptive molecular platforms for pain relief, anti-inflammation, and age-related healthcare issues.
About JZZ Technologies, Inc.
JZZ Technologies, Inc. is a diversified technology company rolling up projects and partnerships in two distinct business sectors that operate cohesively; its digital media business includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted at active adults 55+. The Company's other business is focused on strategic biotechnology and bioscience acquisitions related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for aging populations.
DISCLAIMER and FORWARD-LOOKING STATEMENTS
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; and other risks detailed in the Company's filings with the OTC Markets. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103721